venetoclax,ibrutinib,rituximab
roche,janssen,abbvie,biogen
['ibru', 'venetoclax', 'cll']
interim analysis of the phase 3 ncri flair study at #eha2022: in the first 2 years of treatment, ibrutinib + venetoclax therapy in patients with previously untreated cll resulted in high rates of mrd negativity in the blood and marrow of 71.9% and 65.4%, respectively 